Overview: Hormone refractory prostate cancer

被引：70

作者：

Crawford, ED

Rosenblum, M

Ziada, AM

Lange, PH

机构：

[1] Univ Colorado, Hlth Sci Ctr, Div Urol, Denver, CO 80262 USA

[2] Univ Washington, Sch Med, Dept Urol, Seattle, WA USA

来源：

UROLOGY | 1999年 / 54卷 / 6A期

关键词：

D O I：

10.1016/S0090-4295(99)00447-1

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1 / 7

页数：7

共 42 条

[11]

CRAWFORD ED, 1998, CONT UROLOGY, V10, P43

[12] GROWTH-FACTORS IN DEVELOPMENT, TRANSFORMATION, AND TUMORIGENESIS [J].

CROSS, M ;

DEXTER, TM .

CELL, 1991, 64 (02) :271-280

[13] Development of angiogenesis inhibitors for cancer therapy [J].

Eckhardt, SG ;

Pluda, JM .

INVESTIGATIONAL NEW DRUGS, 1997, 15 (01) :1-3

[14]

EISENBERGER M A, 1988, NCI (National Cancer Institute) Monographs, P151

[15] Bilateral orchiectomy with or without flutamide for metastatic prostate cancer [J].

Eisenberger, MA ;

Blumenstein, BA ;

Crawford, ED ;

Miller, G ;

McLeod, DG ;

Loehrer, PJ ;

Wilding, G ;

Sears, K ;

Culkin, DJ ;

Thompson, IM ;

Bueschen, AJ ;

Lowe, BA .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (15) :1036-1042

[16]

FAIR WR, 1992, CAMPBELLS UROLOGY, P1031

[17]

GOLDENBERG SL, 1995, UROLOGY, V45, P839

[18] ESTIMATING THE COST-EFFECTIVENESS OF TOTAL ANDROGEN BLOCKADE WITH FLUTAMIDE IN M1 PROSTATE-CANCER [J].

HILLNER, BE ;

MCLEOD, DG ;

CRAWFORD, ED ;

BENNETT, CL .

UROLOGY, 1995, 45 (04) :633-640

[19] Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer [J].

Hudes, GR ;

Nathan, F ;

Khater, C ;

Haas, N ;

Cornfield, M ;

Giantonio, B ;

Greenberg, R ;

Gomella, L ;

Litwin, S ;

Ross, E ;

Roethke, S ;

McAleer, C .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (09) :3156-3163

[20] THE TIMING OF ANDROGEN ABLATION THERAPY AND OR CHEMOTHERAPY IN THE TREATMENT OF PROSTATIC-CANCER [J].

ISAACS, JT .

PROSTATE, 1984, 5 (01) :1-17

← 1 2 3 4 5 →